cs-8080
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00613431)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- LXR-alphaAGONIST
NR1H3 agonist
discontinued in 2008, did not meet criteria in clinical trials (http://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005144/imm2009_01_30_26_01.pdf)
- LXR-betaAGONIST
NR1H2 agonist
discontinued in 2008, did not meet criteria in clinical trials (http://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005144/imm2009_01_30_26_01.pdf)
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545238 ↗
Also known as
- cs8080
- cs-8080
- cs-8080
- cs-8080
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00796575 | Phase 1 | Nov 1, 2008 | Daiichi Sankyo |
| NCT00613431 | Phase 1 | Jan 1, 2008 | Daiichi Sankyo, MDS Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 2 | 2 | 1 | 2008 |
| MDS Pharma | For profit | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1